Monte Rosa Therapeutics (GLUE) News Today $7.67 -0.01 (-0.13%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of DirectorsDecember 13, 2024 | globenewswire.comMonte Rosa Therapeutics presents preclinical data on CDK2 degraderDecember 11, 2024 | markets.businessinsider.comMonte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue DegradersDecember 11, 2024 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast CancerDecember 11, 2024 | globenewswire.comMonte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 8.7% - Should You Buy?December 8, 2024 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Monte Rosa Therapeutics (GLUE) and CAMP4 Therapeutics Corporation (CAMP)December 6, 2024 | markets.businessinsider.comMonte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 8.7% - Still a Buy?Monte Rosa Therapeutics (NASDAQ:GLUE) Trading 8.7% Higher - What's Next?December 6, 2024 | marketbeat.comMonte Rosa Highlights Promising Results in Cancer StudyDecember 5, 2024 | markets.businessinsider.comMonte Rosa Therapeutics provides development progress on ongoing MRT-2359 studyDecember 5, 2024 | markets.businessinsider.comMonte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid TumorsDecember 5, 2024 | globenewswire.comMonte Rosa Therapeutics: A First AssessmentDecember 4, 2024 | seekingalpha.comMonte Rosa Therapeutics to Participate in the Piper Sandler Healthcare ConferenceNovember 26, 2024 | globenewswire.comShort Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Expands By 49.9%Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 7,840,000 shares, an increase of 49.9% from the October 15th total of 5,230,000 shares. Based on an average daily trading volume, of 2,080,000 shares, the short-interest ratio is presently 3.8 days. Approximately 17.0% of the shares of the stock are short sold.November 16, 2024 | marketbeat.comMonte Rosa Therapeutics to Participate in the Jefferies London Healthcare ConferenceNovember 13, 2024 | markets.businessinsider.comWhat is Wedbush's Forecast for GLUE FY2028 Earnings?Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Equities research analysts at Wedbush upped their FY2028 earnings estimates for Monte Rosa Therapeutics in a report issued on Thursday, November 7th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share oNovember 11, 2024 | marketbeat.comMonte Rosa Therapeutics Expands Pipeline with Novartis DealNovember 9, 2024 | markets.businessinsider.comMonte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 8, 2024 | markets.businessinsider.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Major Shareholder Versant Venture Capital Vi, L. Sells 89,990 SharesOctober 31, 2024 | insidertrades.comWedbush Research Analysts Raise Earnings Estimates for GLUEMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Stock analysts at Wedbush boosted their FY2024 earnings estimates for shares of Monte Rosa Therapeutics in a report issued on Monday, October 28th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per shareOctober 30, 2024 | marketbeat.comMonte Rosa Therapeutics Gains Momentum with Strategic NVS Partnership and Positive Market ResponseOctober 29, 2024 | markets.businessinsider.comMonte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with NovartisOctober 29, 2024 | finance.yahoo.comMonte Rosa Therapeutics price target raised to $20 from $16 at Piper SandlerOctober 28, 2024 | markets.businessinsider.comMonte Rosa Stock Doubles — Up 127% — On A Massive Deal With NovartisOctober 28, 2024 | msn.comMonte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 52-Week High - Time to Buy?Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 1-Year High - Here's WhyOctober 28, 2024 | marketbeat.comThis Biotech Stock Has Doubled Its Value Today—Here's WhyOctober 28, 2024 | investopedia.comMonte Rosa Therapeutics Target of Unusually Large Options Trading (NASDAQ:GLUE)Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) saw unusually large options trading on Monday. Stock traders bought 1,500 call options on the stock. This represents an increase of 2,532% compared to the average daily volume of 57 call options.October 28, 2024 | marketbeat.comMonte Rosa Therapeutics Shares Soar on Novartis Team-UpOctober 28, 2024 | marketwatch.comMonte Rosa jumps on $150M license deal with NovartisOctober 28, 2024 | msn.comWhy Is Monte Rosa Therapeutics Stock Surging On Monday?October 28, 2024 | finance.yahoo.comMonte Rosa Inks License Agreement With Novartis To Advance VAV1 MGDsOctober 28, 2024 | markets.businessinsider.comMonte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue DegradersOctober 28, 2024 | globenewswire.comMonte Rosa Therapeutics presents preclinical data at ENA 2024October 24, 2024 | markets.businessinsider.comMonte Rosa Therapeutics (NASDAQ:GLUE) Stock, Short Interest ReportOctober 11, 2024 | benzinga.comRenaissance Technologies LLC Has $953,000 Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Renaissance Technologies LLC increased its stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 108.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 254,714 shares of the company's stock after pOctober 7, 2024 | marketbeat.comVersant Venture Capital Vi, L. Sells 1,132,566 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) StockSeptember 25, 2024 | insidertrades.comVersant entities sell over $3.4 million in Monte Rosa Therapeutics stockSeptember 15, 2024 | uk.investing.comInsider Selling: Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Major Shareholder Sells $57,097.04 in StockSeptember 14, 2024 | insidertrades.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Major Shareholder Versant Venture Capital Vi, L. Sells 9,269 SharesMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) major shareholder Versant Venture Capital Vi, L. sold 9,269 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $6.16, for a total transaction of $57,097.04. Following the completion of the transaction, the insider now owns 6,231,902 shares of the company's stock, valued at $38,388,516.32. The sale was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.September 13, 2024 | marketbeat.comMonte Rosa Therapeutics (NASDAQ:GLUE) Receives "Outperform" Rating from WedbushWedbush reissued an "outperform" rating and issued a $11.00 target price on shares of Monte Rosa Therapeutics in a report on Thursday.September 12, 2024 | marketbeat.comMonte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 3.3%Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 3.3%September 5, 2024 | marketbeat.comCompanies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In GrowthAugust 24, 2024 | finance.yahoo.comMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 StudyAugust 20, 2024 | finanznachrichten.deMonte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 StudyAugust 19, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)August 13, 2024 | markets.businessinsider.comMonte Rosa Therapeutics (NASDAQ:GLUE) Price Target Cut to $17.00Wells Fargo & Company reduced their price objective on Monte Rosa Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Monday.August 12, 2024 | marketbeat.comTD Cowen Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)August 9, 2024 | markets.businessinsider.comMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 8, 2024 | finanznachrichten.deMonte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 8, 2024 | globenewswire.comPrice T Rowe Associates Inc. MD Buys 155,880 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Price T Rowe Associates Inc. MD lifted its stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 3.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,096,787 shares of theAugust 1, 2024 | marketbeat.comMonte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation DayJuly 8, 2024 | globenewswire.com Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now GLUE Media Mentions By Week GLUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLUE News Sentiment▼0.160.75▲Average Medical News Sentiment GLUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLUE Articles This Week▼41▲GLUE Articles Average Week Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HRMY News GLPG News XNCR News EVO News ARQT News RCUS News NRIX News IMCR News KNSA News OCUL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLUE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
